試題詳解

15. Why are monoclonal antibody therapies less effective against emerging SARS-CoV-2 variants?
(A) Variants replicate slower than antibodies can bind.
(B) Mutations in non-spike proteins prevent antibody binding.
(C) Antibody production is delayed in vaccinated individuals.
(D) Mutations in spike epitopes reduce antibody binding affinity.

(E) Monoclonal antibodies degrade too quickly in the bloodstream.